Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Alexion Pharmaceuticals Inc. ALXN

Healthcare Biotechnology
Alexion Pharmaceuticals specializes in developing and marketing drugs for rare, life-threatening medical conditions. Its blockbuster product, Soliris, is approved for paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). Next-generation Ultomiris is approved in PNH and aHUS... see more

Recent & Breaking News (NDAQ:ALXN)

Rady Children’s Institute for Genomic Medicine and Alexion Pharmaceuticals Partner to Speed the Diagnosis of Rare Genetic Disorders in Newborns

Business Wire May 16, 2017

Long-term Data Confirm Benefits of Treatment with Strensiq® (asfotase alfa) in Adolescents and Adults with Hypophosphatasia (HPP) Through Five Years

Business Wire May 15, 2017

Alexion Global Headquarters Earns Highest LEED® Green Building Certification

Business Wire May 11, 2017

Alexion to Present at the Bank of America Merrill Lynch 2017 Health Care Conference

Business Wire May 9, 2017

Alexion Shares Under Pressure Amid Brazilian Office Raid; Barclays Says Buy The Dip

Benzinga.com  May 9, 2017

Alexion Reports First Quarter 2017 Results

Business Wire April 27, 2017

How These Biotech Stocks are Faring? -- ACADIA Pharma, Alexion Pharma, TG Therapeutics, and Esperion Therapeutics

PR Newswire April 24, 2017

Alexion to Report First Quarter 2017 Results on Thursday, April 27, 2017

Business Wire April 6, 2017

Alexion Appoints Ludwig Hantson, Ph.D., as Chief Executive Officer

Business Wire March 27, 2017

Alexion Submits Application in Japan for Soliris® (Eculizumab) as a Potential Treatment for Patients with Refractory Generalized Myasthenia Gravis (gMG)

Business Wire March 22, 2017

15 Biggest Mid-Day Gainers For Friday

Benzinga.com  March 17, 2017

Mid-Morning Market Update: Markets Edge Higher; Tiffany Earnings Top Estimates

Benzinga.com  March 17, 2017

Arbutus Licenses LNP Delivery Technology to Alexion for Use in Single Messenger RNA Product Candidate

GlobeNewswire March 16, 2017

Options Traders Alert: Covered Call reports for Alexion Pharmaceuticals, Alibaba, Intel, Mobileye NV and Micron

PR Newswire March 14, 2017

FDA Accepts sBLA Filing of Soliris® (Eculizumab) as a Potential Treatment for Patients with Refractory Generalized Myasthenia Gravis (gMG)

Business Wire March 8, 2017

Leonard Bell, M.D., Alexion’s Founder, Announces Plans to Retire as Chairman and Board Member

Business Wire March 2, 2017

Alexion to Present at Upcoming Investor Conferences

Business Wire February 27, 2017

Alexion Reports Fourth Quarter and Full Year 2016 Results and Provides Financial Guidance for 2017

Business Wire February 16, 2017

Technical Reports on Biotech Stocks -- Amgen, Array BioPharma, Merrimack Pharma, and Alexion Pharma

PR Newswire February 6, 2017

Alexion Pharmaceuticals to Report Fourth Quarter and Full Year 2016 Results on Thursday, February 16, 2017

Business Wire January 26, 2017